AC Immune SA has shared exciting news from their tests of two new treatments for early Alzheimer’s disease. These treatments, ACI-35.030 and JACI-35.054, are designed to target a specific part of a protein called Tau, which is involved in Alzheimer’s disease. ACI-35.030 was created using a special technology called SupraAntigen. The tests showed that ACI-35.030 worked quickly and effectively after just one dose. It created strong and lasting protection against harmful forms of the Tau protein. All participants showed a response within two weeks, and this response lasted up to 74 weeks in those who received higher doses. Importantly, it did not affect the normal Tau protein after subsequent doses. On the other hand, JACI-35.054 had a less consistent response and needed multiple doses to work effectively. It also started affecting the normal Tau protein after the second dose. Both treatments were safe and well-tolerated. Based on these results, ACI-35.030 (also known as JNJ-2056) is now being tested in a larger study with around 500 participants who are at risk of developing Alzheimer’s disease. Dr. Andrea Pfeifer, the CEO of AC Immune SA, said, ‘These results show that ACI-35.030 was safe and effective at all tested doses. It worked quickly and lasted longer than other similar treatments. This study also shows that our SupraAntigen technology can create unique and effective treatments, even when using the same target as others.’